What CorMedix's Reaffirmed Revenue Guidance and New CMS Add-On Rate Mean for DefenCath in 2027 (NASDAQ:CRMD)

Sonal Goyal

03 November 2026 07:02 PM AEDT

What CorMedix's Reaffirmed Revenue Guidance and New CMS Add-On Rate Mean for DefenCath in 2027 (NASDAQ:CRMD)

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Revenue Guidance Reaffirmed: CorMedix is maintaining its full-year 2026 total Revenue guidance of $325 million to $345 million.
Q3 Cash Position: The company reported approximately $355 million in cash and cash equivalents as of September 30, 2026.
2027 CMS Add-On Rate: CMS has set a post-TDAPA Add-On payment for DefenCath of $8.32 per dialysis session for Q1 2027, within the company's previously guided range of 3x to 5x the current $2.37 rate.
Quarterly Adjustment Process: CMS also introduced a new quarterly process for calculating Add-On adjustments, which will affect how DefenCath's reimbursement rate evolves throughout 2027.

CorMedix Therapeutics(NASDAQ:CRMD), the commercial-stage biopharmaceutical company behind DefenCath—the only FDA-approved catheter lock solution for reducing bloodstream infections in hemodialysis patients—has issued a Business update ahead of its full Earnings Call expected on November 12, 2026. The company is standing behind its annual revenue forecast and provided early clarity on a key reimbursement metric that will shape the product's commercial trajectory into 2027.

Guidance and Cash Position

The maintenance of the $325 million to $345 million revenue guidance for full-year 2026 signals that CorMedix does not see any material deviation from its August forecast based on third quarter activity. The company separately disclosed that it held approximately $355 million in cash as of September 30, 2026, a figure that represents a meaningful financial cushion relative to its operating requirements and indicates the company is not facing near-term Capital constraints.

DefenCath, which contains taurolidine and heparin, is designed to be instilled in hemodialysis catheters between dialysis sessions to prevent catheter-related bloodstream infections—a serious and costly complication in the dialysis population. The drug has been commercially available and reimbursed under CMS payment systems, and the dynamics of that reimbursement are central to understanding CorMedix's near-term revenue trajectory.

The 2027 CMS Add-On and Quarterly Adjustment Framework

The CMS released its 2027 End-Stage Renal Disease Prospective Payment System final rule on October 28, 2026. The rule set a post-TDAPA Add-On payment for DefenCath of $8.32 per dialysis session for Q1 2027. That figure is above the current $2.37 Add-On in effect for Q3 and Q4 2026 and falls within the 3x to 5x range CorMedix had previously communicated to the market as its expectation.

Equally significant is the introduction of a new quarterly process for calculating Add-On adjustments. This mechanism means the $8.32 rate for Q1 2027 may not remain static throughout the year—it will be recalculated on a quarterly basis, introducing a degree of variability into DefenCath's effective reimbursement rate over the course of 2027. CorMedix noted that it is aware of statements from a large dialysis organization (LDO) during that organization's investor call regarding the quarterly trajectory, but the company has not provided explicit forward guidance for the Q2-Q4 2027 period at this time.

Risks

The quarterly adjustment mechanism for the CMS Add-On introduces meaningful uncertainty. If the recalculated rates in Q2 through Q4 2027 decline from the Q1 level, CorMedix's revenue per session could compress during the year in ways that are difficult to predict or offset through Volume growth. The large dialysis organizations that control a significant share of treatment volume are also influential in how DefenCath is adopted and prescribed—any changes in their approach to formulary management or reimbursement strategy could affect uptake.

DefenCath's commercial success depends on sustained use by dialysis providers. The product currently occupies a relatively unique regulatory position, but competitive developments in catheter infection prevention could emerge over time.

What to Watch Next

The November 12 earnings call will be the key near-term event, as CorMedix is expected to provide full third quarter financial details including revenue, margins, and a more complete commercial update. Any guidance or commentary on how the company expects the quarterly CMS Add-On adjustment to evolve across 2027 will be closely watched by investors trying to model DefenCath's revenue contribution in the coming year.

Sector Context

DefenCath occupies a specific niche within the end-stage renal disease treatment market. The dialysis market in the United States is characterized by a small number of very large operators who collectively manage the majority of treatment sessions, giving them substantial Leverage in negotiations around drug adoption and formulary inclusion. CMS payment policy plays an outsized role in determining DefenCath's commercial appeal, because most dialysis patients are covered under Medicare's bundled ESRD payment system.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.